NCT01144624 - A Study to Assess Safety,and Tolerability of 2 Doses of AZD9773 (CytoFab™) in Japanese With Severe Sepsis/Septic Shock | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Severe SepsisSeptic Shock

Interventions

DRUG

AZD9773

A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days

DRUG

Placebo

Intravenous infusion of a saline solution

Trial Locations (7)

Research Site, Sapporo

Research Site, Kobe

Research Site, Kumamoto

Research Site, Osaka

Research Site, Sumiyoshi-ku

Research Site, Hachiōji

Research Site, Ohta-ku